SI3447050T1 - Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze - Google Patents

Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze

Info

Publication number
SI3447050T1
SI3447050T1 SI201531117T SI201531117T SI3447050T1 SI 3447050 T1 SI3447050 T1 SI 3447050T1 SI 201531117 T SI201531117 T SI 201531117T SI 201531117 T SI201531117 T SI 201531117T SI 3447050 T1 SI3447050 T1 SI 3447050T1
Authority
SI
Slovenia
Prior art keywords
pyridin
mutant
isocitrate dehydrogenase
dehydrogenase inhibitors
quinolinone derivatives
Prior art date
Application number
SI201531117T
Other languages
English (en)
Slovenian (sl)
Inventor
Susan Ashwell
Ann-Marie Campbell
Justin Andrew Caravella
R. Bruce Diebold
Anna Ericsson
Gary Gustafson
David R. Lancia Jr.
Jian Lin
Wei Lu
Zhongguo Wang
Original Assignee
Forma Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics, Inc. filed Critical Forma Therapeutics, Inc.
Publication of SI3447050T1 publication Critical patent/SI3447050T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
SI201531117T 2014-09-19 2015-09-18 Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze SI3447050T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US201562150812P 2015-04-21 2015-04-21
EP18198969.0A EP3447050B1 (en) 2014-09-19 2015-09-18 Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
SI3447050T1 true SI3447050T1 (sl) 2020-08-31

Family

ID=54291606

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201531117T SI3447050T1 (sl) 2014-09-19 2015-09-18 Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze
SI201530537T SI3194376T1 (sl) 2014-09-19 2015-09-18 Derivati piridin-2(1H)-on kinolona kot inhibitorji mutirane izocitrat dehidrogenaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201530537T SI3194376T1 (sl) 2014-09-19 2015-09-18 Derivati piridin-2(1H)-on kinolona kot inhibitorji mutirane izocitrat dehidrogenaze

Country Status (37)

Country Link
US (8) US9834539B2 (enExample)
EP (4) EP4257131A3 (enExample)
JP (1) JP6648115B2 (enExample)
KR (1) KR102209667B1 (enExample)
CN (3) CN117695280A (enExample)
AU (3) AU2015317329B2 (enExample)
BR (1) BR112017005238B1 (enExample)
CA (1) CA2961817C (enExample)
CL (1) CL2017000658A1 (enExample)
CO (1) CO2017003241A2 (enExample)
CY (2) CY1121149T1 (enExample)
DK (2) DK3447050T3 (enExample)
EA (1) EA034336B1 (enExample)
EC (1) ECSP17022933A (enExample)
ES (3) ES2704897T3 (enExample)
FI (1) FI3733662T3 (enExample)
HR (1) HRP20200666T1 (enExample)
HU (2) HUE062424T2 (enExample)
IL (3) IL292608B2 (enExample)
LT (2) LT3194376T (enExample)
MA (2) MA53352A (enExample)
ME (1) ME03776B (enExample)
MX (2) MX2017003404A (enExample)
MY (2) MY197533A (enExample)
NZ (1) NZ730373A (enExample)
PE (1) PE20171056A1 (enExample)
PH (1) PH12017500517B1 (enExample)
PL (3) PL3447050T3 (enExample)
PT (3) PT3733662T (enExample)
RS (2) RS58184B1 (enExample)
SA (1) SA517381129B1 (enExample)
SG (1) SG11201702194SA (enExample)
SI (2) SI3447050T1 (enExample)
SM (2) SMT201900018T1 (enExample)
TW (1) TWI686390B (enExample)
WO (1) WO2016044789A1 (enExample)
ZA (3) ZA201702127B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
EP3064595B1 (en) * 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
JP6479029B2 (ja) 2014-02-06 2019-03-06 ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited ムスカリンm1受容体アゴニストとしての二環式アザ化合物
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
CA2961811C (en) 2014-09-19 2021-11-02 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
AU2015317321B2 (en) * 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
CR20170100A (es) 2014-09-19 2017-04-24 Bayer Pharma Aktiengesellchaft Indazoles sustituidos con bencilo como inhibidores bub1
PL3447050T3 (pl) 2014-09-19 2020-07-27 Forma Therapeutics, Inc. Chinolinonowe pochodne pirydyn-2(1H)-onu jako inhibitory zmutowanej dehydrogenazy izocytrynianowej
CA2971872C (en) * 2014-12-22 2023-10-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant idh1 inhibitors useful for treating cancer
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
HRP20220790T1 (hr) 2017-05-04 2022-09-16 Bayer Cropscience Aktiengesellschaft Derivati 2-{[2-(feniloksimetil)piridin-5-il]oksi}etanamina i srodni spojevi kao pesticidi, primjerice namijenjeni zaštiti bilja
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
PT3720442T (pt) 2018-05-16 2023-03-13 Forma Therapeutics Inc Inibição de idh-1 mutante
EP4215197A1 (en) 2018-05-16 2023-07-26 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
JP2005532368A (ja) 2002-06-12 2005-10-27 アボット・ラボラトリーズ メラニン濃縮ホルモン受容体の拮抗薬
JPWO2004043936A1 (ja) 2002-11-14 2006-03-09 協和醗酵工業株式会社 Plk阻害剤
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
EP1749827A4 (en) 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd ANTITUMOR AGENTS
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
JP2009543867A (ja) * 2006-07-17 2009-12-10 メルク エンド カムパニー インコーポレーテッド 抗hiv剤としての1−ヒドロキシナフチリジン化合物
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規2環性複素環化合物
DK2152676T3 (da) 2007-04-30 2013-07-01 Prometic Biosciences Inc Triazinderivater, sammensætninger, der indeholder sådanne derivater, og fremgangsmåde til behandling af cancer og autoimmunsygdomme ved anvendelse af sådanne derivater
CN102573485B (zh) 2009-06-08 2014-11-26 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
CN104271132B (zh) 2011-12-21 2018-01-12 科罗拉多大学董事会法人团体 靶向Ral GTP酶的抗癌化合物及使用其的方法
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
AU2014229283B2 (en) * 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
AU2015317321B2 (en) 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
CA2961811C (en) 2014-09-19 2021-11-02 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
PL3447050T3 (pl) 2014-09-19 2020-07-27 Forma Therapeutics, Inc. Chinolinonowe pochodne pirydyn-2(1H)-onu jako inhibitory zmutowanej dehydrogenazy izocytrynianowej
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
CA2971872C (en) 2014-12-22 2023-10-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant idh1 inhibitors useful for treating cancer
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
MX390396B (es) 2016-02-26 2025-03-20 Celgene Corp Enasidenib para usarse en leucemia mieloide aguda recidivante o refractaria.
US10696665B2 (en) 2016-06-06 2020-06-30 Eli Lilly And Company Mutant IDH1 inhibitors
ES2880347T3 (es) 2016-06-22 2021-11-24 Us Health Derivados de tiazol útiles como inhibidores de IDH1 mutante para el tratamiento del cáncer
RS61108B1 (sr) 2016-12-16 2020-12-31 Lilly Co Eli Jedinjenja 7-feniletilamino-4h-pirimido[4,5-d][1,3]oksazin-2-ona kao inhibitori idh1 i idh2 mutanta

Also Published As

Publication number Publication date
PT3447050T (pt) 2020-09-17
US20240150319A1 (en) 2024-05-09
US9834539B2 (en) 2017-12-05
US20160083366A1 (en) 2016-03-24
SMT201900018T1 (it) 2019-02-28
ZA202304409B (en) 2024-08-28
JP6648115B2 (ja) 2020-02-14
US20180312487A1 (en) 2018-11-01
US20210078973A1 (en) 2021-03-18
IL282363B (en) 2022-06-01
US12275715B2 (en) 2025-04-15
WO2016044789A1 (en) 2016-03-24
KR20170063742A (ko) 2017-06-08
AU2019283765A1 (en) 2020-01-16
MA40481A (fr) 2017-07-26
CN107001328A (zh) 2017-08-01
TWI686390B (zh) 2020-03-01
SA517381129B1 (ar) 2021-04-26
MX2019013203A (es) 2020-01-20
CN117695280A (zh) 2024-03-15
IL292608B2 (en) 2024-10-01
PE20171056A1 (es) 2017-07-21
EP3194376A1 (en) 2017-07-26
NZ730373A (en) 2019-11-29
EP3194376B1 (en) 2018-10-24
SMT202000212T1 (it) 2020-05-08
IL251163B (en) 2021-05-31
ZA201702127B (en) 2019-06-26
MY197533A (en) 2023-06-21
EP3447050A1 (en) 2019-02-27
LT3194376T (lt) 2019-02-25
MY176250A (en) 2020-07-24
MX2017003404A (es) 2017-07-28
PL3733662T3 (pl) 2024-01-22
RS60140B1 (sr) 2020-05-29
MX385512B (es) 2025-03-18
CY1121149T1 (el) 2020-05-29
ES2704897T3 (es) 2019-03-20
EA201790657A1 (ru) 2017-08-31
US11498913B2 (en) 2022-11-15
EP3447050B1 (en) 2020-02-19
EP3733662B1 (en) 2023-06-07
JP2017528487A (ja) 2017-09-28
US10414752B2 (en) 2019-09-17
IL251163A0 (en) 2017-04-30
LT3447050T (lt) 2020-05-11
US20190263778A1 (en) 2019-08-29
CA2961817A1 (en) 2016-03-24
HUE062424T2 (hu) 2023-11-28
EA201790657A8 (ru) 2018-02-28
ES2953347T3 (es) 2023-11-10
IL282363A (en) 2021-06-30
CN111909130A (zh) 2020-11-10
IL292608A (en) 2022-07-01
SG11201702194SA (en) 2017-04-27
AU2021215141A1 (en) 2021-09-02
CY1122865T1 (el) 2021-05-05
EP3733662A1 (en) 2020-11-04
RS58184B1 (sr) 2019-03-29
FI3733662T3 (fi) 2023-08-09
PH12017500517A1 (en) 2017-08-07
CA2961817C (en) 2024-03-12
US10550098B2 (en) 2020-02-04
AU2021215141B2 (en) 2023-10-19
AU2015317329A1 (en) 2017-04-27
AU2015317329B2 (en) 2019-10-31
ME03776B (me) 2021-04-20
BR112017005238B1 (pt) 2023-01-17
EP4257131A3 (en) 2024-01-10
US20170174658A1 (en) 2017-06-22
MA53352A (fr) 2021-09-15
EP4257131A2 (en) 2023-10-11
PH12017500517B1 (en) 2022-08-03
PT3733662T (pt) 2023-08-18
US20200223822A1 (en) 2020-07-16
CL2017000658A1 (es) 2017-12-22
HUE041460T2 (hu) 2019-05-28
ECSP17022933A (es) 2017-08-31
TW201617335A (zh) 2016-05-16
PT3194376T (pt) 2019-02-04
US20230125739A1 (en) 2023-04-27
CN111909130B (zh) 2023-10-31
US10889567B2 (en) 2021-01-12
AU2019283765B2 (en) 2021-05-13
DK3447050T3 (da) 2020-03-09
PL3447050T3 (pl) 2020-07-27
PL3194376T3 (pl) 2019-05-31
SI3194376T1 (sl) 2019-03-29
NZ758641A (en) 2023-12-22
CO2017003241A2 (es) 2017-09-20
KR102209667B1 (ko) 2021-01-29
CN107001328B (zh) 2020-06-05
IL292608B1 (en) 2024-06-01
EA034336B1 (ru) 2020-01-29
ES2790640T3 (es) 2020-10-28
DK3194376T3 (en) 2019-01-21
BR112017005238A2 (pt) 2017-12-19
ZA201902446B (en) 2023-12-20
HRP20200666T1 (hr) 2020-07-24

Similar Documents

Publication Publication Date Title
IL282363B (en) History of pyridine-2(1h)-one quinolinone as mutant dehydrogenase inhibitors-isocitrate
ZA202007274B (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
IL247970A (en) Quinoline history as smo inhibitors
EP3239147A4 (en) Quinoline derivative
IL249674A0 (en) Quinolizinone derivatives as inhibitors of pi3k
ZA201700883B (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EP3097101A4 (en) Isoquinoline derivatives as mgat2 inhibitors
GB201403595D0 (en) Quinoline compounds
AU2014900040A0 (en) Processes for preparing 8-hydroxy quinoline derivatives